Feeds › Planned insider sales
Planned insider sales
Notices (SEC Form 144) that executives and other insiders file before selling shares, and whether a sale was reported afterwards.
About this data
- What it is
- Before an executive, director or large owner sells restricted or control shares, they file a short notice with the SEC, called Form 144, saying how many shares they plan to sell, through which broker and roughly when. This feed lists those notices, and for each one shows whether a sale was reported afterwards on a Form 4 and how many days later.
- Who files it
- The person selling, or their broker, on the day the sale is placed. Electronic notices start in April 2023.
- How current
- We collect new notices throughout the day on SEC business days.
- Terms
- Form 144The notice an insider or other affiliate of a company files with the SEC before selling restricted or control shares, so the shares can be sold under Rule 144. The notice says how many shares, through which broker, and roughly when.10b5-1 planA Rule 10b5-1 trading plan lets an insider set up future sales in advance, on a schedule or at set prices, at a time when they do not hold inside information. A notice that gives a plan adoption date says the sale is made under such a plan.
- Worth knowing
- A notice is a plan, not a sale: the person may sell fewer shares, later, or not at all. The value is the one the filer typed, at a price they chose, not what the shares sell for. Many sales are routine, made to diversify or pay taxes, or under a 10b5-1 plan set up months earlier. A blank in the last column does not mean no sale: the person may not have to file a Form 4 (an ordinary affiliate does not), the sale may be recent, or the Form 4 may name a different spelling of the person. We match by the filer's number first and by name second. Information, not investment advice.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Form 144 notices per day, last 30 days
All notices Notices that give a 10b5-1 plan
By the day each notice was filed. A notice is a plan to sell, not a sale.
Latest notices of planned insider sales
Showing: ticker ELVN
| Filed | Insider | Company | Shares to sellA notice is a plan, not a sale. The person may sell fewer shares, sell later, or not sell at all, and the number of shares is what they expect to sell on the day they file. | ValueThe aggregate market value the filer typed on the notice: the shares times a price the filer chose. It is not what the shares will sell for. | PlanA Rule 10b5-1 trading plan lets an insider set up future sales in advance, on a schedule or at set prices, at a time when they do not hold inside information. A notice that gives a plan adoption date says the sale is made under such a plan. | Expected sale | Sale reportedInsiders who are officers, directors or hold more than 10% report their sales on a Form 4, within two business days. We look for the first Form 4 with an open-market sale by the same person in the same company within 90 days of the notice, and show how many days after the notice it was filed. A blank means we found none: the person may not have sold, may not have to file a Form 4, or the Form 4 may be one we do not have. | Notice |
|---|---|---|---|---|---|---|---|---|
| Oct 19, 2026 | Collins Helen Louise Director | ELVN Enliven Therapeutics, Inc. | 15,000 | $559.8K | 10b5-1 | Oct 19, 2026 | Form 4 ↗ 2 days later · 5,000 shares | Form 144 ↗ |
| Oct 1, 2026 | Jeffrey Garland Director | ELVN Enliven Therapeutics, Inc. | 13,000 | $606.7K | — | Oct 1, 2026 | — | Form 144 ↗ |
| Sep 17, 2026 | Benjamin Hohl Officer | ELVN Enliven Therapeutics, Inc. | 12,036 | $591.2K | 10b5-1 | Sep 17, 2026 | Form 4 ↗ 4 days later · 6,018 shares | Form 144 ↗ |
| Sep 4, 2026 | Richard A. Heyman resigned from BOD | ELVN Enliven Therapeutics, Inc. | 38,000 | $2.3M | — | Sep 4, 2026 | — | Form 144 ↗ |
| Aug 4, 2026 | Mika K. Derynck Director | ELVN Enliven Therapeutics, Inc. | 158,795 | $9.2M | 10b5-1 | Aug 4, 2026 | Form 4 ↗ 2 days later · 158,795 shares | Form 144 ↗ |
| Jul 17, 2026 | Collins Helen Louise Officer | ELVN Enliven Therapeutics, Inc. | 15,000 | $762.9K | 10b5-1 | Jul 17, 2026 | Form 4 ↗ 4 days later · 5,000 shares | Form 144 ↗ |
| Jun 22, 2026 | OrbiMed Genesis Master Fund, L.P. Shareholder | ELVN Enliven Therapeutics, Inc. | 1,477 | $67.9K | — | Jun 22, 2026 | Form 4 ↗ 2 days later · 860,123 shares | Form 144 ↗ |
| Jun 22, 2026 | OrbiMed Genesis Master Fund, L.P. Shareholder | ELVN Enliven Therapeutics, Inc. | 24,846 | $1.1M | — | Jun 22, 2026 | Form 4 ↗ 2 days later · 860,123 shares | Form 144 ↗ |
| Jun 22, 2026 | OrbiMed Private Investments VII, LP Shareholder | ELVN Enliven Therapeutics, Inc. | 46,776 | $2.1M | — | Jun 22, 2026 | Form 4 ↗ 2 days later · 860,123 shares | Form 144 ↗ |
| Jun 22, 2026 | OrbiMed Private Investments VII, LP Shareholder | ELVN Enliven Therapeutics, Inc. | 787,024 | $36.2M | — | Jun 22, 2026 | Form 4 ↗ 2 days later · 860,123 shares | Form 144 ↗ |
| Jun 22, 2026 | The Biotech Growth Trust PLC Shareholder | ELVN Enliven Therapeutics, Inc. | 1,747 | $80.3K | — | Jun 22, 2026 | — | Form 144 ↗ |
| Jun 22, 2026 | The Biotech Growth Trust PLC Shareholder | ELVN Enliven Therapeutics, Inc. | 29,385 | $1.4M | — | Jun 22, 2026 | — | Form 144 ↗ |
| Jun 17, 2026 | Benjamin Hohl Officer | ELVN Enliven Therapeutics, Inc. | 18,054 | $768.2K | 10b5-1 | Jun 17, 2026 | Form 4 ↗ 5 days later · 6,018 shares | Form 144 ↗ |
| Jun 15, 2026 | The Biotech Growth Trust PLC Shareholder | ELVN Enliven Therapeutics, Inc. | 10,243 | $433.9K | — | Jun 15, 2026 | — | Form 144 ↗ |
| Jun 15, 2026 | OrbiMed Private Investments VII, LP Shareholder | ELVN Enliven Therapeutics, Inc. | 272,322 | $11.5M | — | Jun 15, 2026 | Form 4 ↗ 2 days later · 281,408 shares | Form 144 ↗ |
| Jun 15, 2026 | OrbiMed Genesis Master Fund, L.P. Shareholder | ELVN Enliven Therapeutics, Inc. | 9,086 | $384.9K | — | Jun 15, 2026 | Form 4 ↗ 2 days later · 281,408 shares | Form 144 ↗ |
| Jun 5, 2026 | Kunkel Lori Anne Board Member | ELVN Enliven Therapeutics, Inc. | 20,000 | $709.8K | 10b5-1 | Jun 5, 2026 | Form 4 ↗ 4 days later · 10,000 shares | Form 144 ↗ |
| May 18, 2026 | Collins Helen Louise Officer | ELVN Enliven Therapeutics, Inc. | 15,000 | $620.1K | 10b5-1 | May 18, 2026 | Form 4 ↗ 2 days later · 5,000 shares | Form 144 ↗ |
| Apr 30, 2026 | Joseph P. Lyssikatos Officer | ELVN Enliven Therapeutics, Inc. | 25,000 | $1.1M | 10b5-1 | Apr 30, 2026 | — | Form 144 ↗ |
| Mar 31, 2026 | Joseph P. Lyssikatos Officer | ELVN Enliven Therapeutics, Inc. | 25,000 | $914.8K | 10b5-1 | Mar 31, 2026 | — | Form 144 ↗ |
| Mar 31, 2026 | Andrew Phillips Former Director | ELVN Enliven Therapeutics, Inc. | 26,035 | $1.0M | — | Mar 31, 2026 | — | Form 144 ↗ |
| Mar 25, 2026 | Collins Helen Louise Officer | ELVN Enliven Therapeutics, Inc. | 45,000 | $1.4M | 10b5-1 | Mar 25, 2026 | Form 4 ↗ 2 days later · 40,000 shares | Form 144 ↗ |
| Mar 24, 2026 | Patel Anish Officer | ELVN Enliven Therapeutics, Inc. | 100,000 | $3.1M | — | Mar 24, 2026 | — | Form 144 ↗ |
| Mar 9, 2026 | Collins Helen Louise Officer | ELVN Enliven Therapeutics, Inc. | 45,000 | $1.3M | 10b5-1 | Mar 9, 2026 | Form 4 ↗ 2 days later · 40,000 shares | Form 144 ↗ |
| Mar 6, 2026 | Benjamin Hohl Officer | ELVN Enliven Therapeutics, Inc. | 10,000 | $292.9K | — | Mar 6, 2026 | Form 4 ↗ 4 days later · 10,000 shares | Form 144 ↗ |
| Feb 18, 2026 | Joseph P. Lyssikatos Officer | ELVN Enliven Therapeutics, Inc. | 75,000 | $2.0M | 10b5-1 | Feb 18, 2026 | — | Form 144 ↗ |
| Feb 17, 2026 | Samuel Kintz Officer | ELVN Enliven Therapeutics, Inc. | 75,000 | $2.0M | 10b5-1 | Feb 17, 2026 | — | Form 144 ↗ |
| Feb 17, 2026 | Richard A. Heyman Director | ELVN Enliven Therapeutics, Inc. | 1,230 | $32.9K | 10b5-1 | Feb 17, 2026 | Form 4 ↗ 2 days later · 1,230 shares | Form 144 ↗ |
| Feb 17, 2026 | Collins Helen Louise Officer | ELVN Enliven Therapeutics, Inc. | 45,000 | $1.2M | 10b5-1 | Feb 17, 2026 | Form 4 ↗ 2 days later · 45,000 shares | Form 144 ↗ |
| Feb 2, 2026 | Andrew Phillips Former Director | ELVN Enliven Therapeutics, Inc. | 21,844 | $611.7K | — | Feb 2, 2026 | — | Form 144 ↗ |
| Jan 20, 2026 | Richard A. Heyman Director | ELVN Enliven Therapeutics, Inc. | 1,230 | $32.9K | 10b5-1 | Jan 20, 2026 | Form 4 ↗ 2 days later · 1,230 shares | Form 144 ↗ |
| Jan 9, 2026 | Joseph P. Lyssikatos Officer | ELVN Enliven Therapeutics, Inc. | 75,000 | $1.7M | 10b5-1 | Jan 9, 2026 | Form 4 ↗ 3 days later · 132,500 shares | Form 144 ↗ |
| Jan 9, 2026 | Samuel Kintz Officer | ELVN Enliven Therapeutics, Inc. | 75,000 | $1.7M | 10b5-1 | Jan 9, 2026 | — | Form 144 ↗ |
| Jan 9, 2026 | Patel Anish Officer | ELVN Enliven Therapeutics, Inc. | 48,300 | $1.1M | 10b5-1 | Jan 9, 2026 | Form 4 ↗ 4 days later · 48,300 shares | Form 144 ↗ |
| Jan 8, 2026 | Samuel Kintz Officer | ELVN Enliven Therapeutics, Inc. | 82,500 | $1.3M | 10b5-1 | Jan 8, 2026 | — | Form 144 ↗ |
| Jan 8, 2026 | Joseph P. Lyssikatos Officer | ELVN Enliven Therapeutics, Inc. | 82,500 | $1.3M | 10b5-1 | Jan 8, 2026 | Form 4 ↗ 4 days later · 132,500 shares | Form 144 ↗ |
| Jan 8, 2026 | Richard A. Heyman Director | ELVN Enliven Therapeutics, Inc. | 1,620 | $25.1K | 10b5-1 | Jan 8, 2026 | Form 4 ↗ 4 days later · 13,920 shares | Form 144 ↗ |
| Jan 8, 2026 | Richard A. Heyman Director | ELVN Enliven Therapeutics, Inc. | 12,300 | $190.3K | 10b5-1 | Jan 8, 2026 | Form 4 ↗ 4 days later · 13,920 shares | Form 144 ↗ |
| Dec 19, 2025 | Joseph P. Lyssikatos Officer | ELVN Enliven Therapeutics, Inc. | 5,000 | $83.4K | 10b5-1 | Dec 19, 2025 | Form 4 ↗ 4 days later · 5,000 shares | Form 144 ↗ |
| Dec 17, 2025 | Samuel Kintz Officer | ELVN Enliven Therapeutics, Inc. | 5,000 | $84.5K | 10b5-1 | Dec 17, 2025 | — | Form 144 ↗ |
| Dec 8, 2025 | Patel Anish Officer | ELVN Enliven Therapeutics, Inc. | 6,663 | $145.3K | 10b5-1 | Dec 8, 2025 | Form 4 ↗ 2 days later · 6,663 shares | Form 144 ↗ |
| Nov 19, 2025 | Joseph P. Lyssikatos Officer | ELVN Enliven Therapeutics, Inc. | 12,500 | $282.4K | 10b5-1 | Nov 19, 2025 | Form 4 ↗ 2 days later · 12,500 shares | Form 144 ↗ |
| Nov 17, 2025 | Samuel Kintz Officer | ELVN Enliven Therapeutics, Inc. | 12,500 | $275.9K | 10b5-1 | Nov 17, 2025 | Form 4 ↗ 2 days later · 12,500 shares | Form 144 ↗ |
| Oct 20, 2025 | Joseph P. Lyssikatos Officer | ELVN Enliven Therapeutics, Inc. | 12,500 | $267.6K | 10b5-1 | Oct 20, 2025 | Form 4 ↗ 2 days later · 12,500 shares | Form 144 ↗ |
| Oct 17, 2025 | Samuel Kintz Officer | ELVN Enliven Therapeutics, Inc. | 12,500 | $271.9K | 10b5-1 | Oct 17, 2025 | Form 4 ↗ 4 days later · 12,500 shares | Form 144 ↗ |
| Sep 29, 2025 | Benjamin Hohl Officer | ELVN Enliven Therapeutics, Inc. | 4,500 | $90.0K | 10b5-1 | Sep 29, 2025 | Form 4 ↗ 2 days later · 3,250 shares | Form 144 ↗ |
| Sep 19, 2025 | Joseph P. Lyssikatos Officer | ELVN Enliven Therapeutics, Inc. | 12,500 | $249.1K | 10b5-1 | Sep 19, 2025 | Form 4 ↗ 4 days later · 7,000 shares | Form 144 ↗ |
| Sep 17, 2025 | Samuel Kintz Officer | ELVN Enliven Therapeutics, Inc. | 12,500 | $230.4K | 10b5-1 | Sep 17, 2025 | Form 4 ↗ 2 days later · 6,000 shares | Form 144 ↗ |
| Sep 8, 2025 | Patel Anish Officer | ELVN Enliven Therapeutics, Inc. | 20,001 | $403.0K | 10b5-1 | Sep 8, 2025 | Form 4 ↗ 2 days later · 6,667 shares | Form 144 ↗ |
| Aug 27, 2025 | Benjamin Hohl Officer | ELVN Enliven Therapeutics, Inc. | 5,250 | $106.7K | 10b5-1 | Aug 27, 2025 | Form 4 ↗ 2 days later · 3,250 shares | Form 144 ↗ |
The newest 50 items, most recent first. Every row links to the notice on the SEC's site, and to the Form 4 when we found one. Updated Nov 15, 2026, 10:39 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances